Lv1
60 积分 2020-10-14 加入
Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis
1年前
已完结
Discovery of farnesoid X receptor and its role in bile acid metabolism
1年前
已完结
FXR: structures, biology, and drug development for NASH and fibrosis diseases
1年前
已完结
FXR and NASH: an avenue for tissue-specific regulation
1年前
已完结
Drugs and liver injury: a not to be overlooked binomial in COVID-19
1年前
已完结
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
1年前
已完结
FXR: structures, biology, and drug development for NASH and fibrosis diseases
1年前
已完结
Mechanism and Active Components of Qingre Lidan Tablets Alleviate Intrahepatic Cholestasis by Activating the Farnesoid X Receptor
1年前
已完结
Discovery of ( E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis
1年前
已完结
Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism
1年前
已完结
皖公网安备34019202002308
